Art. 31 Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 20…

In forcesince 28 Jan 2019cited 8×
1.

Each application for the authorisation of a medicinal product for veterinary use shall specifically and exhaustively include the particulars and documents as referred to in Articles 12(3), 13, 13a, 13b and 14 of, and Annex I to, Directive 2001/82/EC. These particulars and documents shall take account of the unique, Union nature of the authorisation requested and, otherwise than in exceptional cases relating to the application of the law on trade marks, shall include the use of a single name for the medicinal product.

The application shall be accompanied by the fee payable to the Agency for the examination of the application.

2.

In the case of a veterinary medicinal product containing or consisting of genetically modified organisms within the meaning of Article 2 of Directive 2001/18/EC, the application shall also be accompanied by:

(a)

a copy of the written consent of the competent authorities to the deliberate release into the environment of the genetically modified organisms for research and development purposes, as provided for in Part B of Directive 2001/18/EC or in Part B of Directive 90/220/EEC;

(b)

the complete technical file supplying the information required under Annexes III and IV to Directive 2001/18/EC;

(c)

the environmental risk assessment in accordance with the principles set out in Annex II to Directive 2001/18/EC; and

(d)

the results of any investigations performed for the purposes of research or development.

Articles 13 to 24 of Directive 2001/18/EC shall not apply to veterinary medicinal products containing or consisting of genetically modified organisms.

3.

The Agency shall ensure that the opinion of the Committee for Medicinal Products for Veterinary Use is given within 210 days after the receipt of a valid application.

In the case of a veterinary medicinal product containing or consisting of genetically modified organisms, the opinion of the said Committee must respect the environmental safety requirements laid down by Directive 2001/18/EC. During the process of evaluating applications for marketing authorisations for veterinary medicinal products containing or consisting of genetically modified organisms, necessary consultations shall be held by the rapporteur with the bodies set up by the Union or the Member States in accordance with Directive 2001/18/EC.

4.

The Commission shall, in consultation with the Agency, Member States and interested parties, draw up a detailed guide regarding the form in which applications for authorisation are to be presented.

  • Commission Regulation (EC) No 1234/2008 of 24 November 2008 concerning the examination o…2Law

    … от Директива 2001/83/ЕО и в приложение I към нея, в член 6, параграф 2 и член 31, параграф 2 от Регламент (ЕО) № 726/2004 или в член 7 от Регламент …

  • Commission Regulation (EU) No 712/2012 of 3 August 2012 amending Regulation (EC) No 1234…1Law

    … от Директива 2001/83/ЕО и в приложение I към нея, в член 6, параграф 2 и член 31, параграф 2 от Регламент (ЕО) № 726/2004 или в член 7 от Регламент …

  • Ordonnance du président du Tribunal du 20 juillet 2016. MSD Animal Health Innovation GmbH et Intervet international BV contre Agence européeDecision

    As regards the documentary information which an MA application submitted under the centralised procedure must contain, Article 31 of Regulation No 726/2004 read in conjunction with Article 12 of Directive 2001/82 provides that the …

    20 Jul 2016 · 62015TO0729

  • Judgment of the Court (Third Chamber) of 1 October 2015. Agenzia Italiana del Farmaco (AIFA) and Ministero della Salute v Doc Generici srl.Decision

    … от Директива 2001/83/ЕО и в приложение I към нея, в член 6, параграф 2 и член 31, параграф 2 от Регламент (ЕО) № 726/2004 или в член 7 от Регламент …

    1 Oct 2015 · 62014CJ0452

  • Order of the Vice-President of the Court of 1 March 2017. European Medicines Agency (EMA) v MSD Animal Health Innovation GmbH and Intervet iDecision

    In accordance with the combined provisions of Article 31 of Regulation No 726/2004 and Article 12 of Directive 2001/82, that application must contain, in particular, a quality dossier including particulars on product composition and a …

    1 Mar 2017 · 62016CO0512

  • Regulation (EU) 2019/5Lawamends

  • Regulation (EU) 2022/839Law

    … От член 31, параграф 1, член 34, параграф 1, буква в), член 34, параграф 4, буква д) и член 37, параграф 1, втора алинея от Регламент (ЕО) № 726/2004 …

  • Commission Regulation (EU) No 712/2012 of 3 August 2012 amending Regulation (EC) No 1234…1Law

    … to 14 of Directive 2001/82/EC and Annex I thereto, Articles 8(3) to 11 of Directive 2001/83/EC and Annex I thereto, Articles 6(2) and 31(2) of Regulation (EC) No 726/2004, or Article 7 of Regulation (EC) No 1394/2007; (b) the terms of the …